Positive Data on Osteoarthritis Gene Therapy Generated by GeneQuine and Collaborators Presented at OARSI World Congress (26 – 29 April 2018, Liverpool)

The osteoarthritis gene therapy approach developed by Baylor College of Medicine and GeneQuine demonstrated symptomatic and disease-modifying efficacy in small and large osteoarthritis animal models.

The data, which were largely generated at Baylor College of Medicine and Cornell University, pertain to GeneQuine’s veterinary programs GQ-201 (horse) and GQ-202 (dog) as well as the human program FX201 (formerly known as GQ-203), which Flexion Therapeutics Inc acquired from GeneQuine in 2017. The results were presented by Dr. Matthew Grol of Baylor College of Medicine in a plenary session at the Osteoarthritis Research Society International World Congress in Liverpool, UK on April 29, 2018.

(Image by oarsi.org)